Abstract
Our purpose was to evaluate the late physical and psychosocial difficulties of premenpausal patients treated for a localized breast cancer and to weigh the impact of chemotherapy on long-term quality of life. Two self-administered questionnaires, the EORTC core QLQ-C30 and the breast module (BR23) were mailed to 179 premenopausal node-negative women continuously disease-free, previously enrolled in a trial testing the efficacy of adjuvant CMF chemotherapy (Espié et al, 1997). The core questionnaire evaluates the physical, role, emotional, cognitive and social functioning and global health status. The breast module includes four functional scales: body image, sexual functioning, sexual enjoyment and future perspective. It also includes symptom scales such as arm or breast symptoms. Some specific professional and social states were added. 119 (68%) patients (mean age 54 years, range 30–69) participated. Mean follow-up time since diagnosis was 9.6 years (4–16). 68% had conservative and 32% radical surgery (with reconstructive surgery in 50%). CMF was given to 77 (65%) patients. Irradiation was administered in 75% of patients irrespective of adjuvant therapy. QLQ-C30 scale scores were similar in patients who had or had not received chemotherapy. Disturbance in body image, sex life and breast symptoms did not differ between patients who had or had not received adjuvant CMF. No major socioprofessional difficulties were reported except problems in borrowing from banks not related to past chemotherapy. With long follow-up, most premenopausal women treated for a localized breast cancer cope with the disease and its treatments. Adjuvant CMF chemotherapy does not appear to impair quality of life nor social and professional life in these patients. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M & Takeda F (1993) The EORTC QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376
Barni S & Mondin R (1997) Sexual dysfunction in treated breast cancer patients. Ann Oncol 8: 149–153
Berglund G, Bolund C, Fornander T, Rutqvist LE & Sjoden PO (1991) Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer 27: 1075–1081
Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn HJ & Rudenstam CM (1997) Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. Ann Oncol 8: 825–835
Craig TJ, Comstock GW & Geiser PB (1974) The quality of survival in breast cancer: A case-control comparison. Cancer 33: 1451–1457
Dixon WJ (1992) BMDP statistical software Release 7.0. University of California Press: Berkeley
Dorval M, Maunsell E, Deschênes L, Brisson J & Mâsse B (1998) Long-term quality of life after breast cancer: Comparison of 8-year survivors with population controls. J Clin Oncol 16: 487–494
Dow KH, Ferrell BR, Leigh S, Ly J & Gulasekaram P (1996) An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat 39: 261–273
Early Breast Cancer Trialist’s Collaborative Group (E. B. C. T. C. G) (1998) Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352: 930–942
Espié M, Mignot L, Leleu F, De Roquancourt A, Maylin C, Morvan F, Clot P & Marty M (1997) Improved outcome of node negative breast cancer in premenopausal women with adjuvant CMF: Results of a randomized study. Proc ASCO 16: 141
Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML & Petersen L (1996) Breast cancer survivors: Psychosocial concerns and quality of life. Breast Cancer Res Treat 38: 183–199
Ganz PA, Rowland JH, Meyerowitz BE & Desmond K (1998 a) Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 152: 396–411
Ganz PA, Rowland JH, Desmond K, Meyerowitz BE & Wyatt GE (1998 b) Life after breast cancer: Understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 16: 501–514
Ganz PA, Desmond KA, Belin TR, Meyerowitz BE & Rowland JH (1999) Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17: 2371–2380
Goldhirsch A, Wood WC, Senn HJ, Glick JH & Gelber RD (1995) Fifth international conference on adjuvant therapy of breast cancer, St Gallen, March 1995. International consensus panel on the treatment of primary breast cancer. Eur J Cancer 31A: 1754–1759
Halttunen A, Hietanen P, Jallinoja P & Lonnqvist J (1992) Getting free of breast cancer. An eight-year perspective of the relapse-free patients. Acta Oncol 31: 307–310
Hebert-Croteau N, Brisson J, Latreille J, Gariepy G, Blanchette C & Deschênes L (1999) Time trends in systemic adjuvant treatment for node negative breast cancer. J Clin Oncol 17: 1458–1464
Hietanen PS (1996) Measurement and practical aspects of quality of life in breast cancer. Acta Oncol 35: 39–42
Hughson AV, Cooper AF, McArdle CS & Smith DC (1986) Psychological impact of adjuvant chemotherapy in the first two years after mastectomy. BMJ 293: 1268–1271
Hürny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peteron HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellai D, Goldhirsch A & Senn HJ (1996) Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 347: 1279–1284
Joly F, Henry-Amar M, Arveux P, Reman O, Tanguy A, Pény AM, Lebailly P, Macé-Lesec’h J, Vié B, Génot JY, Busson A, Troussard X & Leporrier M (1996) Late psychosocial sequelae in Hodgkin’s disease survivors: A French population-based case-control study. J Clin Oncol 14: 2444–2453
Kiebert GM, de Haes JCJM & van de Velde CJH (1991) The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: A review. J Clin Oncol 9: 1059–1070
Knobf MT (1986) Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol 4: 678–684
Lindley C, Vasa S, Sawyer WT & Winer EP (1998) Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 16: 1380–1387
Maguire GP, Tait A, Brooke M, Thomas C, Howat JM, Sellwood RA & Bush H (1980) Psychiatric morbidity and physical toxicity associated with adjuvant chemotherapy after mastectomy. BMJ 281: 1179–1180
Maunsell E, Brisson J & Deschenes L (1993) Arm problems and psychological distress after surgery for breast cancer. Can J Surg 36: 315–320
McArdle CS (1979) The emotional and social implication of adjuvant chemotherapy in breast cancer. In Adjuvant therapy of cancer, Salmon SE (ed) pp 319–325, Crune and Stratton: Orlando
Osoba D, Zee B, Warr D, Kaizer L & Latreille J (1994) Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast ovarian and lung cancer. Qual Life Res 3: 353–364
Palmer BV, Walsh GA, McKinna JA & Greening WP (1980) Adjuvant chemotherapy for breast cancer: Side effects and quality of life. BMJ 281: 1594–1597
Schover LR, Yetman RJ, Tuason LJ, Meisler E, Esselstyn CB, Hermann RE, Grundfest-Broniatowski S & Dowden RV (1995) Partial mastectomy and breast reconstruction. A comparison of their effects on psychosocial adjustment, body image, and sexuality. Cancer 75: 54–64
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A & Aaronson NK (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J Clin Oncol 14: 2756–2768
van Dam FS, Schagen SB, Muller MJ, Boogerd W, Wall VD, Droogleever FME & Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90: 210–218
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Joly, F., Espié, M., Marty, M. et al. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer 83, 577–582 (2000). https://doi.org/10.1054/bjoc.2000.1337
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1337
Keywords
This article is cited by
-
Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events
Archives of Toxicology (2022)
-
Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors
Health and Quality of Life Outcomes (2020)
-
Quality of life in “chronic” cancer survivors: a meta-analysis
Journal of Cancer Survivorship (2020)
-
Sexual health in long-term breast cancer survivors
Breast Cancer Research and Treatment (2018)
-
Sexual function and chemotherapy in postmenopausal women with breast cancer
BMC Women's Health (2012)